Geneva, Switzerland, June 10, 2020.
Abologix has been named one of the winners of the Venture Kick stage I start up competition.
“We are very pleased and honored to have been chosen by Venture Kick in the latest round of competition. Venture Kick is a reference institution in Switzerland for start-ups and investors alike. We are thrilled about this most recent endorsement of our company and our projects”.
said Ignacio Faus, co-founder and Chairman of the Board of Abologix.
Geneva, Switzerland, December 18, 2019.
Abologix has received recognition in “Bilan” as one of the most promising swiss start-ups in the french speaking cantons of Switzerland. The company has been invited to address a group of potential investors in a future meeting to be held in Lausanne, Switzerland.
Geneva, Switzerland, July 24, 2019
Abologix has obtained impressive data with its anti-JAM-C recombinant monoclonal antibody rH225 in an animal Mantle Cell Lymphoma (MCL) NOD/SCID mouse model.
In this study the efficacy of rH225 was tested by assessing:
the delayed mortality upon Jeko-1 MCL cell injection and
the reduction of Jeko-1 cells burden in the blood, spleen, lymph nodes, bone marrow and liver
rH225 delayed significantly the body weight loss and the onset of clinical disease signs in mice inoculated with Jeko-1 MCL cells. Survival of mice was significantly improved.
Splenomegaly was observed in control antibody-treated animals, but not in rH225-treated mice, suggesting that the treatment effectively prevented spleen infiltration by Jeko-1 cells. Indeed, flow cytometry data revealed that treatment with rH225 significantly decreased the Jeko-1 burden in the spleen, liver, lymph nodes, blood and blood marrow.
“We are very pleased that antibody rH225 blocked infiltration in all lymphoid organs as well as in bone marrow. Inhibiting access of tumour cells to survival niches constitutes a potential new strategy for lymphoma treatment”.
said Prof. Beat Imhof and Prof. Thomas Matthes, scientific co-founders of Abologix.